It is shown that the published hypercholesterolemia PRS (PGS000936) can effectively stratify risk and identify individuals with a high genetic burden in a real-world German clinical setting, supporting its clinical utility when appropriately calibrated for the local population.
Abstract
Polygenic risk scores (PRS) have emerged as promising tools for stratifying inherited disease risk, yet their translation into clinical practice is constrained by a critical and frequently unmet requirement: demonstration that scores derived in one cohort retain discriminatory value when applied independently in a different population. For suspected familial hypercholesterolemia (FH), a substantial proportion of patients that meet clinical criteria still test negative for a monogenic cause. These patients are presumed to carry polygenic LDL-C burden, yet PRS validation is still scarce. Here, we evaluated a published hypercholesterolemia PRS (PGS000936) spanning 5,386 genome-wide loci. We tested the score in 117 monogenic-negative hypercholesterolemia cases and 496 controls from the German general population genotyped on the Illumina Global Screening Array v3.0, with imputation to approximately 11 million variants. The score was applied without retraining, using externally derived {beta}-coefficients. The PRS clearly distinguished cases from controls (p < 2x10-16), with a mean PRS of 0.97 in cases versus 0.52 in controls. Decile analysis revealed a seven-fold increase in odds of hypercholesterolemia in the top 10% of the distribution (OR 7.55; 95% CI 4.36-13.07; p < 0.0001). In 94 cases for which clinical data was available, higher PRS was associated with significantly higher LDL-C levels before treatment. Importantly, the PRS distribution in the German control cohort was shifted relative to that of the control cohort in the initial study, suggesting that population-matched calibration is required for accurate odds ratio estimation and proper interpretation of PRS values. These findings show that the published hypercholesterolemia PRS (PGS000936) can effectively stratify risk and identify individuals with a high genetic burden in a real-world German clinical setting, supporting its clinical utility when appropriately calibrated for the local population.
A multiancestry polygenic risk score for hypertrophic cardiomyopathy is developed and its association with the disease in a heterogeneous national population is demonstrated and support the integration of multiancestry PRSs into HCM risk assessment and prognostication.
Harshvir S. Bal, A. Pampana, Amrita Nayak et al.· Nature Cardiovascular Resear...· 0 citations
This review summarizes the principles of PRS, the main sources of variability between models, and its potential applications in risk stratification and personalized cancer screening and addresses limitations in transferability, the need for calibration, and the currently limited evidence for improvements in hard clinic...
Adéla Mišove, E. Macháčková, Klára Nováková et al.· Klinicka onkologie· 0 citations
The current state of bench-to-bedside translation of polygenic risk scores (PRS) is reviewed and it is shown that quality standards must be established to ensure that the potential of PRS can be effectively translated into routine clinical practice.
Johannes Schumacher, V. Koch, C. Maj et al.· Deutsches Ärzteblatt Interna...· 0 citations
This review outlines four major PRS-informed design strategies: tail sampling based on PRS extremes; discordance sampling based on mismatch between phenotype and PRS-implied risk; conditional and stratified genome-wide association analyses using PRS to adjust for / partition background risk; and residual phenotype anal...
Hui-Qi Qu, H. Hakonarson· Human Genetics· 0 citations
Investigating the utility of genome-wide association study - derived PRS and pathway-specific PRS in the Latvian population and demonstrating superior discrimination compared to pathway-specific PRS found incorporation of PRS enhances early-onset CAD risk prediction.
E. Kanašniece, Elita Ozola, L. Bardina et al.· American Heart Journal Plus:...· 0 citations
For most diseases, whether PRS improves prediction beyond clinical data remains unknown, as existing evidence is concentrated in a handful of conditions with established risk models. Using 900,000 participants from UK Biobank and FinnGen, we developed and validated models for predicting 150 diseases and all-cause morta...
D. Usoltsev, I. Molotkov, N. Kolosov et al.· medRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.